A phase 2b study on 317 patients found ritlecitinib and brepocitinib effective in treating moderate-to-severe ulcerative colitis over 8 weeks. Both drugs significantly improved Total Mayo Score compared to placebo, with higher doses being more effective. Many patients achieved clinical remission, and adverse events were mostly mild, including some infections and isolated serious cases not related to the drugs. The study confirms the efficacy and safety of both drugs as induction therapies for ulcerative colitis.
Reference: Sandborn WJ, Danese S, Leszczyszyn J, et al. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol. 2023 Sep;21(10):2616-2628.e7. doi: 10.1016/j.cgh.2022.12.029. Epub 2023 Jan 6. PMID: 36623678.
Link: https://www.cghjournal.org/article/S1542-3565(23)00007-1/fulltext
